A Multi-center, Randomized, Double-Blind, Parallel Comparative, Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin Versus Levofloxain in Treating Adult Patients With CAP

Trial Profile

A Multi-center, Randomized, Double-Blind, Parallel Comparative, Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin Versus Levofloxain in Treating Adult Patients With CAP

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 May 2017

At a glance

  • Drugs Nemonoxacin (Primary) ; Levofloxacin
  • Indications Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors TaiGen Biotechnology
  • Most Recent Events

    • 30 May 2017 According to a company media release, TaiGen Biotechnology has submitted a New Drug Application (NDA) for the intravenous formulation of Taigexyn (Nemonoxacin) to the China Food and Drug Administration (CFDA). The NDA submission was supported by the results of this trial.
    • 11 Jan 2016 Planned number of patients changed from 540 to 603, according to ClinicalTrials.gov record.
    • 11 Jan 2016 Planned End Date changed from 1 Feb 2016 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top